Global Travel Vaccine Market, By Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine, and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio, and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric, and Geriatric), Age Group (20-50 Years, Less than 20 Years, and Above 50 Years), Distribution Channel (B2B and B2C) - Industry Trends and Forecast to 2032.
Travel Vaccine Market Analysis and Insights
With globalization and easier access to travel, more people are journeying to destinations around the world. This heightened travel activity leads to greater exposure to infectious diseases prevalent in different regions, driving the demand for travel vaccines to protect individuals from contracting diseases like yellow fever, typhoid, hepatitis A, and others. Although, one of the primary restraints for travel vaccines is the cost and accessibility. Travel vaccines can be expensive, especially for individuals who may be traveling to multiple destinations requiring different vaccinations. Additionally, access to healthcare services and vaccination clinics may be limited in certain regions, making it challenging for travelers to receive the necessary vaccinations before their trips. Advances in vaccine technology, such as the development of new delivery methods or more efficient manufacturing processes, present opportunities to improve the efficacy, accessibility, and affordability of travel vaccines. Innovations like DNA vaccines, mRNA vaccines, or microneedle patches could potentially enhance the development and distribution of travel vaccines, making them more widely available and cost-effective. Although, vaccine hesitancy and misinformation pose significant challenges for travel vaccines. Some individuals may be reluctant to receive vaccinations due to concerns about safety, efficacy, or misconceptions about the diseases they protect against. Addressing vaccine hesitancy and combating misinformation through education, outreach efforts, and communication campaigns is crucial to ensure that travelers understand the importance of vaccines in protecting their health and preventing the spread of infectious diseases across borders.
Data Bridge Market Research analyzes that the global travel vaccine market is expected to reach USD 13.09 billion by 2032 from USD 6.14 billion in 2023, growing at a substantial CAGR of 8.9% in the forecast period of 2024 to 2032.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2032
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine, and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio, and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric, and Geriatric), Age Group (20-50 Years, Less than 20 Years, and Above 50 Years), Distribution Channel (B2B and B2C)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Poland, Norway, Hungary, Austria, Ireland, Lithuania, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, Kuwait, and Rest of Middle East and Africa
|
|
Market Players Covered
|
GSK plc., Bavarian Nordic, Pfizer Inc., Abbott, CSL, AstraZeneca, Sanofi, Merck & Co., Inc., Valneva SE, Johnson & Johnson Services Inc., and Dynavax Technologies, among others
|
Market Definition
Travel vaccines are immunizations specifically designed to protect individuals from infectious diseases that they may encounter while traveling to different regions or countries. These vaccines are administered before departure to destinations where there is a risk of exposure to diseases that are not prevalent in the individual's home country or region. The types of vaccines recommended depend on various factors including the traveler’s destination, duration of stay, activities planned, current health status, and any previous immunizations. The goal of travel vaccines is to prevent the extent of infectious diseases and ensure the health and safety of travelers during their journeys.
Global Travel Vaccine Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Incidence of Infectious Diseases
As infectious diseases spread or re-emerge in various parts of the world, travelers face an elevated risk of exposure to these pathogens during their journeys. Travelers may come into contact with infectious agents through interactions with local populations, contaminated food or water, insect bites, or exposure to environmental hazards. The heightened risk of infection underscores the importance of vaccination as a preventive measure to protect travelers from potentially serious or life-threatening diseases. The rising incidence of infectious diseases drives the growth of the travel vaccine market by increasing the risk to travelers, prompting mandatory vaccination requirements, responding to outbreaks and epidemics, promoting preventive measures for endemic diseases, and addressing global health security concerns.
- Government Regulations and Recommendations Regarding Vaccination
Many countries have implemented mandatory vaccination requirements for travelers entering their borders. These requirements are often based on the prevalence of certain diseases in specific regions and aim to avert the importation and spread of infectious diseases. For example, countries in Africa and South America may require proof of yellow fever vaccination for travelers arriving from regions where the disease is endemic. Such mandates create a direct demand for travel vaccines among travelers who need to comply with entry regulations.
Hence, government regulations and recommendations regarding vaccination play a pivotal role in driving the growth of the travel vaccine market by creating demand, raising awareness, and facilitating access to vaccination services for travelers. These efforts are essential for safeguarding public health and minimizing the risk of disease transmission during international travel.
Opportunity
- Advancements in Vaccine Technology
Emerging vaccine platforms, such as mRNA vaccines and viral vector vaccines, offer new opportunities for the development of travel vaccines. These innovative platforms allow for the rapid design and production of vaccines against a wide range of pathogens, comprising those responsible for travel-related diseases. By leveraging novel vaccine platforms, researchers can accelerate the development of next-generation travel vaccines with improved efficacy and broader coverage against multiple diseases.
Advances in vaccine technology enable the design of vaccines with enhanced immunogenicity, resulting in stronger and longer-lasting immune responses. Novel adjuvants, delivery systems, and antigen design strategies enhance vaccine efficacy by stimulating robust immune responses and inducing protective immunity against targeted pathogens. By improving vaccine efficacy, technological advancements increase the effectiveness of travel vaccines in preventing diseases and reducing the risk of infection among travelers.
Restraints/Challenges
- Cold Chain Requirements for Storage
Cold chain infrastructure, including refrigeration equipment, temperature monitoring devices, and storage facilities, is essential for maintaining vaccine potency during storage and transportation. However, many regions, particularly in low- and middle-income countries and remote areas, lack adequate cold chain infrastructure. The absence of reliable electricity, refrigeration facilities, and transportation networks complicates cold chain management and compromises vaccine storage conditions. As a result, vaccine distribution and access may be limited in regions with inadequate cold chain infrastructure, hindering the growth of the travel vaccine market.
Vaccines must be stored and transported within a specific temperature range to prevent heat or cold exposure that could compromise their efficacy. However, temperature fluctuations during transportation, such as exposure to extreme heat or freezing temperatures, can damage vaccines and render them ineffective. Ensuring temperature stability and monitoring during transit can be challenging, especially in regions with harsh environmental conditions or unreliable transportation systems. Temperature-sensitive vaccines, such as those requiring ultra-low temperature storage, face additional challenges in maintaining stability during transport, further complicating cold chain management and limiting vaccine accessibility.
- High Cost of Travel Vaccines
For many individuals, especially those traveling on a budget or to low-income countries, the cost of travel vaccines can be prohibitive. Travelers may need to pay out-of-pocket for vaccines, as they are not always covered by health insurance plans. The cumulative cost of multiple vaccines recommended for travel to certain regions can add up quickly, leading some travelers to forgo vaccination altogether or to prioritize other travel expenses over vaccination. As a result, the high cost of travel vaccines may deter some individuals from seeking vaccination services, thereby limiting the growth of the travel vaccine market.
The high cost of travel vaccines exacerbates existing disparities in access to healthcare services. Individuals from marginalized or underserved communities, who may already face financial constraints in accessing healthcare, are disproportionately affected by the high cost of travel vaccines. This unequal access to vaccination services can contribute to gaps in vaccination coverage among travelers, particularly among those from low-income backgrounds. As a result, the growth of the travel vaccine market may be hindered by barriers to access imposed by the high cost of vaccines.
Recent Developments
- In March 2024, Pfizer Inc. announced that the European Commission (EC) has granted marketing approval for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumonia in infants, children and adolescents from 6 weeks to less than 18 years of age
- In October 2023, GSK plc. announced that it has reached an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to promote GSK's Zhifei vaccine in China for the first three years. Cooperation can be continued with the consent of all parties. Zhifei, China's largest vaccine company, has acquired innovative vaccines from China. By combining the scale and expertise of the two companies, the strategic partnership will significantly expand the availability of Shingrix, supporting rapid expansion of the vaccine to patients and future potential indications
- In October 2022, Merck & Co., Inc., known as MSD outside the United States and Canada, declared today that the European Commission (EC) has approved an expanded indication for VAXNEUVANCE (15-valent pneumococcal conjugate vaccine), which includes active immunization for prevention. For the treatment of invasive disease, pneumonia and acute otitis media affected by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years. The approval facilitates the availability of VAXNEUVANCE to this population in all 27 member states of the European Union (EU), as well as in Iceland, Norway and Liechtenstein
- In September 2022, AstraZeneca announces that doses of FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal) are now available in the United States for the 2022-2023 influenza season. FLUMIST QUADRIVALENT, the only Food and Drug Administration (FDA)-approved nasal spray influenza vaccine, is indicated for ages 2 to 49.1 years. According to the 2022-2023 recommendations of the Immunization Practices Advisory Committee (ACIP) from Centers for Disease Control and Prevention (CDC). And the American Academy of Pediatrics (AAP), FLUMIST QUADRIVALENT remains an alternative to flu vaccination in the United States this season. The CDC emphasizes that the most effective protection against seasonal flu is the annual flu vaccine. This approval will help the company to expand their business
- In February 2021, In February, Johnson & Johnson Services Inc. announced that the U.S. Food and Drug Administration (FDA) has delivered Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, established by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This has helped the company to strengthen its product portfolio
Global Travel Vaccine Market Scope
The global travel vaccine market is segmented into nine notable segments which are based on composition, type, category, disease, route of administration, gender, patient type, age group, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Composition
- Combination Vaccines
- Mono Vaccines
On the basis of composition, the market is segmented into combination vaccines and mono vaccines.
Type
- Inactivated Vaccines
- Subunit, Recombinant, Polysaccharide and Conjugate Vaccines
- Live-Attenuated Vaccines
- Toxoid Vaccines
- DNA Vaccines
- Viral Vector Vaccines
On the basis of type, the market is segmented into inactivated vaccines, subunit, recombinant, polysaccharide and conjugate vaccines, live-attenuated vaccines, toxoid vaccines, DNA vaccines, and viral vector vaccines.
Category
- Recommended Vaccine
- Routine Vaccine
- Required Vaccine
On the basis of category, the market is segmented into recommended vaccine, routine vaccine, and required vaccine.
Disease
- Typhoid
- Hepatitis
- Cholera
- Varicella
- Influenza
- Japanese Encephalitis
- Meningococcal Meningitis
- Yellow Fever
- Rabies
- DPT
- Measles and Mumps
- Tick-Borne Encephalitis
- Malaria
- Covid-19
- Polio
- Others
On the basis of disease, the market is segmented into typhoid, hepatitis, cholera, varicella, influenza, Japanese encephalitis, meningococcal meningitis, yellow fever, rabies, DPT, measles and mumps, tick-borne encephalitis, malaria, covid-19, polio, and others.
Route of Administration
- Injectable
- Oral
On the basis of route of administration, the market is segmented into injectable and oral.
Gender
- Male
- Female
On the basis of gender, the market is segmented into male and female.
Patient Type
- Adult
- Pediatric
- Geriatric
On the basis of patient type, the market is segmented into adult, pediatric, and geriatric.
Age Group
- 20-50 Years
- Less than 20 Years
- Above 50 Years
On the basis of age group, the market is segmented into 20-50 years, less than 20 years, and above 50 years.
Distribution Channel
- B2B
- B2C
On the basis of distribution channel, the market is segmented into B2B and B2C.
Global Travel Vaccine Market Regional Analysis/Insights
The global travel vaccine market is segmented into nine notable segments which are based on composition, type, category, disease, route of administration, gender, patient type, age group, and distribution channel.
The countries covered in this market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Poland, Norway, Hungary, Austria, Ireland, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, Kuwait, and rest of Middle East and Africa.
North America is expected to dominate the global travel vaccine market with a favorable reimbursement policies for dialysis treatment. The U.S. is expected to dominate in the North America region due to the presence of major market players and improving development and research in healthcare sector. India is expected to dominate in the Asia-Pacific region due to its vast landmass and large pool of geriatric patients. Germany is expected to dominate in the Europe region due to its advanced technology adoption, robust healthcare infrastructure, and mature market.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Travel Vaccine Market Share Analysis
The global travel vaccine market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the global travel vaccine market.
Some of the major market players operating in the global travel vaccine market are GSK plc., Bavarian Nordic, Pfizer Inc., Abbott, CSL, AstraZeneca, Sanofi, Merck & Co., Inc., Valneva SE, Johnson & Johnson Services Inc., and Dynavax Technologies, among others.
SKU-